Latest News

This is a much smaller investment than that in yesterday’s news.  Mirus’s focus has been in the area of muscular dystrophy.  BD 

NEW YORK (GenomeWeb News) – Roche said today that it will buy RNAi technologies company Mirus Bio Corporation for $125 million.

Roche plans to divest Mirus’ transfection reagents into a stand-alone business called Mirus Bio LLC, and it expects to offer employees of the Madison, Wis.-based company a transition into respective business units. The Swiss firm intends to retain an RNAi research site at the facilities in Madison.

http://www.genomeweb.com/issues/news/148322-1.html?CMP=OTC-RSS

0 comments :

Post a Comment

:) :)) ;(( :-) =)) ;( ;-( :d :-d @-) :p :o :>) (o) [-( :-? (p) :-s (m) 8-) :-t :-b b-( :-# =p~ $-) (b) (f) x-) (k) (h) (c) cheer
Click to see the code!
To insert emoticon you must added at least one space before the code.

 
Top
Google Analytics Alternative